Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy.

导出 LinkOut

翻译打印收藏纠错

第一作者： Xiu-Juan,Liu

第一单位： School of Pharmacy, Lanzhou University, Lanzhou 730000, China.

作者： Xiu-Juan,Liu ^[1] ; Hong-Cheng,Zhao ^[2] ; Su-Juan,Hou ^[1] ; Hao-Jie,Zhang ^[1] ; Lei,Cheng ^[1] ; Shuo,Yuan ^[3] ; Li-Rong,Zhang ^[4] ; Jian,Song ^[5] ; Sai-Yang,Zhang ^[6] ; Shi-Wu,Chen ^[7]

作者单位： School of Pharmacy, Lanzhou University, Lanzhou 730000, China. ^[1] Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Medical College of China Three Gorges University, Yichang 443003, China. ^[2] Children's Hospital Affiliated to Zhengzhou University, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou 450018, China. ^[3] Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China. ^[4] Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China. Electronic address: mumuandzz@163.com. ^[5] Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou 450001, China. Electronic address: saiyangz@zzu.edu.cn. ^[6] School of Pharmacy, Lanzhou University, Lanzhou 730000, China. Electronic address: chenshw@lzu.edu.cn. ^[7]

关键词 Anticancer activities Multi-targeting capabilities Rational design VEGFR-2